Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Effective against Omicron, the Health Yuan COVID-19 vaccine booster has been submitted for market approval.

Published Time:

2022-02-18

Based on existing COVID-19 vaccines, how can we improve their effectiveness against the Omicron variant? Sequential booster immunization (also known as "heterologous booster immunization") is considered one of the important areas of exploration.

 

Recently, the interim primary data analysis of the Phase III clinical trial for the sequential booster of "Recombinant Novel Coronavirus Fusion Protein Vaccine" (V-01), developed by CSPC Pharmaceutical Group's indirectly held subsidiary, CSPC Meibiao Biopharmaceutical, has been completed, and key data has been obtained.

 

On the afternoon of February 18, Zhu Baoguo, Chairman of CSPC Pharmaceutical Group, told a reporter from Yicai Global that as of February 18, the company has begun submitting an application to Chinese regulatory authorities for V-01 as a sequential booster vaccine for COVID-19, and applications to other countries are also underway.

 

It is worth noting that the Phase III clinical trial plan for the V-01 sequential booster is the world's first randomized, double-blind Phase III clinical trial to study the sequential booster protection against Omicron.

 

V-01, initiated in July 2020, is an innovative recombinant protein vaccine for COVID-19 jointly developed by CSPC Meibiao Biopharmaceutical and the Institute of Biophysics, Chinese Academy of Sciences. The V-01 molecule consists of four parts: interferon, Pan epitope, RBD dimer, and Fc fusion protein.

 

This sequential booster program is designed for sequential boosting based on two doses of inactivated vaccines. The Phase III clinical trial for sequential boosting was conducted in Pakistan and Malaysia. It is planned to include a total of 10,722 healthy adults aged 18 and above who have completed two doses of inactivated vaccines 3-6 months prior. Participants will be randomly assigned (1:1) to receive either a V-01 booster shot or a placebo.

 

As of the date of this key data analysis, 10,241 participants were actually enrolled, and a total of 110 cases of the primary endpoint were monitored after vaccination (the protocol requires analysis after at least 103 cases of the primary endpoint). According to the results of the current analysis, compared with two doses of inactivated vaccines, the incidence rate per person-year in the V-01 sequential booster group and the two-dose inactivated vaccine group was 6.73% and 12.80%, respectively, showing a significant difference (P=0.0012); the absolute protective efficacy of V-01 sequential booster was 61.35%, showing significantly superior efficacy. Genotyping sequencing of 60 samples from this trial showed that all were Omicron (others are undergoing next-generation sequencing), indicating that V-01 sequential boosting can provide good protection against COVID-19 caused by Omicron infection. No safety concerns of note were found.

 

"This clinical trial uses a superior efficacy standard for relative protection, which is different from the traditional placebo-controlled approach. The 61.35% absolute protection data obtained this time is based on the protective efficacy of inactivated vaccines and the data generated under the prevalence of Omicron, which also meets the WHO standards." Jin Fang, chief scientist of CSPC Pharmaceutical Group, told Yicai Global.

 

Jin Fang also said that the V-01 vaccine uses conventional adjuvants, has good safety, and the adverse reaction rate is much lower than that of all non-inactivated vaccines. Currently, 90% of the raw materials can be domestically produced, and imported raw materials are also conventional materials with multiple suppliers, stable supply chain, and sufficient reserves. Alternative development work has been carried out, and efforts are being made to achieve complete domestic production of raw materials. In addition, the current annual production capacity of the bulk solution in the CSPC Meibiao Biopharmaceutical commercialization workshop can reach 3.5 billion doses; the production capacity of three formulation lines can reach 120 million doses/month, and the annual production capacity can reach 1.5 billion doses. In emergencies, contract manufacturing can be considered to further expand production capacity.

 

Source: Yicai Global